Patents Assigned to Xiamen University
  • Publication number: 20170073488
    Abstract: The present invention provides a kind of inherent flame retardant rigid polyurethane foam. The production formula comprises 100 to 105 pbw of polyether polyol and reactive phosphorus-containing flame retardant, 2.5 to 3.5 pbw of amine catalyst, 0.8 to 2.5 pbw of tertiary amine catalyst, 0.8 to 2.5 pbw of foam stabilizer, 0.5 to 1.5 pbw of blowing agent, 135 to 150 pbw of isocyanates, and 0.05 to 0.1 pbw of organo-metallic catalyst, wherein the reactive phosphorus-containing flame retardant is 9,10-dihydro-9-oxa-10-phosphaphenanthrene-4-hydroxybenzyl alcohol. The active monomers containing flame retarding elements are introduced into main chain and side chain of PU for modification, which permanently improves the flame retardancy of PU without obvious effect on other performance of PU matrix.
    Type: Application
    Filed: December 4, 2014
    Publication date: March 16, 2017
    Applicant: XIAMEN UNIVERSITY
    Inventors: Lizong DAI, Cong XIE, Wei'ang LUO, Birong ZENG, Yiting XU, Xinyu LIU, Kaibin HE, Qi LI, Yuanyuan LI, Xianming CHEN
  • Publication number: 20170044474
    Abstract: A membrane photobioreactor for treating nitrogen and phosphorus that are out of limits in a biogas slurry and treating method thereof, relating to biogas slurry treatment. The membrane photobioreactor for treating nitrogen and phosphorus that are out of limits in a biogas slurry is provided with a biogas slurry storage tank, peristaltic pumps, a microalgae cultivating tank, an air pump, a membrane photobioreactor and a hollow fiber membrane.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 16, 2017
    Applicant: XIAMEN UNIVERSITY
    Inventors: Qingbiao Li, Xi Chen, Ning He, Yuanpeng Wang, Liang Shen, Haitao Wang
  • Publication number: 20170029855
    Abstract: The present application provides a method for simultaneously synthesizing a biological flocculant with polysaccharide and ?-PGA as the active components by using Bacillus licheniformis. Bacillus licheniformis is inoculated to a slant culture medium to be cultured; a single colony on a fresh plate is inoculated to a seed culture medium to be cultured; and a seed fermentation broth is inoculated to a fermentation culture medium to be cultured, and then the biological flocculant having two different components is obtained. The flocculant synthesized in the present invention is high in activity and good in thermal stability; and especially, the flocculation effect of polysaccharide is relatively superior under acidic and neutral conditions, and the flocculation activity of ?-PGA is relatively higher under neutral and alkaline environments, which can satisfy a relatively large pH application range.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 2, 2017
    Applicant: XIAMEN UNIVERSITY
    Inventors: Ning He, Haosheng Yao, Yu Liu, Wencheng Yu, Shan Yan, Yuanpeng Wang, Qingbiao Li
  • Patent number: 9533035
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: January 3, 2017
    Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.
    Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
  • Publication number: 20160379742
    Abstract: The present invention provides a POSS-containing in-situ composite nanogel with magnetic responsiveness and the method for preparing the same, wherein POSS-containing macromolecule capable of polymerizing and metal-coordination complexing is synthetized to complex with iron salt, Fe2+/Fe3+ salts are in-situ deposited via chemical coprecipitation, and crosslinking agent and initiator are added to induce polymerization so that POSS-containing nanogel ranges with magnetic responsiveness is obtained. The present invention is of professional design, feasible technique and simple operation, and prepared nanogel magnetic particles are well dispersed with excellent magnetic responsiveness, which possesses a good application prospect in medical diagnosis, sensor, catalyst carrier and biomaterial.
    Type: Application
    Filed: December 5, 2014
    Publication date: December 29, 2016
    Applicant: XIAMEN UNIVERSITY
    Inventors: LIZONG DAI, LINGNAN CHEN, YUEGUANG WU, BIRONG ZENG, JIE MAO, SHUANG WANG, YITING XU, WEI'ING LUO, KAIBIN HE, XINYU LIU
  • Patent number: 9512185
    Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: December 6, 2016
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
  • Patent number: 9499591
    Abstract: Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: November 22, 2016
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Shaowei Li, Xiaobing Mo, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
  • Publication number: 20160298002
    Abstract: A new approach for preparation and use of adhesive for metal and fabric bonding is proposed in this invention. Generally, 80-120 g of epoxy resin, 10-30 g of reactive diluent, 0.5-5 g siliane coupling agent, 0.5-5 g metallic oxide nanopowder and 35-60 g curing agent are applied in the formula. With the treatment of silane coupling agent and the mixture of phosphoric acid and nitric acid respectively, the active groups are introduced onto the surface of the metal and the fabric, which enhanced the adhesive strength of metal/fabric interface. Simultaneously, the brittleness, poor cracking and impact resistance of the traditional epoxy adhesive are also optimized by using the method of this invention, which is easy to operate and widely used.
    Type: Application
    Filed: November 5, 2014
    Publication date: October 13, 2016
    Applicants: XIAMEN UNIVERSITY, Fujian Longxi Bearing (Group) Corp., Ltd.
    Inventors: LIZONG DAI, JIE MAO, FANPEL ZHENG, LINGNAN CHEN, ZHIXIONG CHEN, BIRONG ZHENG, LIANGJIA ME, YITING XU, WEI'ANG LUO, XIASHENG XU, ZHAOCHANG WANG
  • Patent number: 9428554
    Abstract: The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: August 30, 2016
    Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.
    Inventors: Ningshao Xia, Jun Zhang, Ying Gu, Shaowei Li, Shengxiang Ge, Zhiqiang He
  • Patent number: 9428555
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: August 30, 2016
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Ying Gu, Shaowei Li, Minxi Wei, Yangling Xian, Wenxin Luo, Ningshao Xia
  • Publication number: 20160208431
    Abstract: The present invention provides a fluorine-containing self-lubricating fabric coating material and method for preparing the same. The coating material consists of 30 to 70 pbw of fluorine resin, 10 to 40 pbw of a curing agent, 5 to 25 pbw of a reactive diluents, 0.5 to 5 pbw of a silane coupling agent and 0.5 to 3 pbw of a silicon surfactant. It is of high fluorine content and high stability. Besides, the coating material system with characteristics of self-lubricating and weather resistance is solvent-free, environmentally friendly, and has wide applications.
    Type: Application
    Filed: August 13, 2014
    Publication date: July 21, 2016
    Applicant: XIAMEN UNIVERSITY
    Inventors: Lizong DAI, Jie MAO, Lingnan CHEN, Yiting XU, Birong ZENG, Wuhui QIU, Cunfeng SONG, Wei'ang LUO, Qilong KANG
  • Publication number: 20160194490
    Abstract: The present invention provides a method for preparing high-strength cross-linked polymer photonic crystal film by core-shell polymer microspheres via evaporation-induced self assembly. Monodispersed core-shell polymer microspheres are fabricated by emulsifier-free emulsion polymerization, and then the microspheres emulsion is coated onto suitable substrates. Finally, polymer photonic crystal film with long-range ordered is constructed via self assembly. Self-cross-linking between the two units improves the strength of the polymer photonic crystal film, therefore the preparation of large size industrial-grade photonic crystal film is practicable which extends its application on the field of dyeing.
    Type: Application
    Filed: August 13, 2014
    Publication date: July 7, 2016
    Applicant: XIAMEN UNIVERSITY
    Inventors: Lizong Dai, Shirong YU, Conghui Yuan, Long Zhang, Lina Zhong, Cunfeng Song, Yiting Xu, Birong Zeng, Wei'ang Luo
  • Patent number: 9382296
    Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: July 5, 2016
    Assignees: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.
    Inventors: Shaowei Li, Minxi Wei, Xianglin Kong, Yingbin Wang, Jun Zhang, Ningshao Xia
  • Patent number: 9364529
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: June 14, 2016
    Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen University
    Inventors: Shaowei Li, Wentong Shen, Zhongyi Li, Minghui Xie, Huirong Pan, Ningshao Xia
  • Patent number: 9359639
    Abstract: The present invention discloses a method for detecting multiple single nucleotide variations or polymorphisms in a single reaction tube, and the oligonucleotide, the probe, the set of probes, the kit used, as well as the use thereof. Specifically, it relates to a method for identifying the genotype of multiple single nucleotide variation or SNP sites from the melting temperature of a kind of artificial melting temperature tag sequence (AMTS) and the type of fluorescence labels.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: June 7, 2016
    Assignee: XIAMEN UNIVERSITY
    Inventors: Qingge Li, Qiuying Huang, Xiaobo Wang
  • Publication number: 20160129138
    Abstract: Disclosed are nanoparticles comprising octapod iron oxide having eight trigonal bipyramidal arms and a method of preparing the same. The nanoparticles are prepared by heating a mixture of a ferric carboxylate, a carboxylic acid, a chloride salt, water, and a non-polar solvent, to a temperature above about 300° C. Also disclosed is a method of magnetic resonance imaging a tissue in a mammal, comprising use of the aforesaid nanoparticles.
    Type: Application
    Filed: June 3, 2013
    Publication date: May 12, 2016
    Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV, XIAMEN UNIVERSITY
    Inventors: Jinhao Gao, Xiaoyuan Chen, Zenghuan Zhao
  • Patent number: 9334533
    Abstract: The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: May 10, 2016
    Assignee: XIAMEN UNIVERSITY
    Inventors: Qingge Li, Qiuying Huang
  • Publication number: 20160031972
    Abstract: The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 4, 2016
    Applicants: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN UNIVERSITY
    Inventors: Zizheng Zheng, Jason S. McLellan, Man Chen, Min Zhao, Liangmin Huang, Barney S. Graham, Ningshao Xia
  • Patent number: 9249193
    Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: February 2, 2016
    Assignees: Xiamen University, Xiamen Innovax Biotech Co. Ltd.
    Inventors: Shaowei Li, Xianglin Kong, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
  • Patent number: 9222090
    Abstract: The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: December 29, 2015
    Assignees: XIAMEN UNIVERSITY, YANG SHENG TANG COMPANY LIMITED
    Inventors: Tong Cheng, Tao Zhang, Yali Zhang, Ji Miao, Jun Zhang, Ningshao Xia